MARSHA MILLER: Open Payments
NPI 1306259296 · NEW HAVEN, CT. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$820 in 33 payments from 10 companies in 2025. Trend: 2023 $440 · 2024 $445 · 2025 $820
Food & beverage: $820
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation | 8 | $174 |
| Novo Nordisk Inc | 4 | $104 |
| Merck Sharp & Dohme LLC | 4 | $100 |
| PFIZER INC. | 4 | $98 |
| Alnylam Pharmaceuticals Inc. | 3 | $88 |
| Lilly USA, LLC | 3 | $80 |
| Bayer Healthcare Pharmaceuticals Inc. | 3 | $71 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 2 | $44 |
| Boston Scientific Corporation | 1 | $32 |
| AstraZeneca Pharmaceuticals LP | 1 | $26 |
Products named: LEQVIO, VERQUVO, Wegovy, ELIQUIS, Kerendia, AMVUTTRA, MOUNJARO, JARDIANCE.
Industry payments across CT — which companies pay providers there.
